NLST低剂量CT肺癌筛查全队列器官剂量评估
本研究回顾性纳入NLST中25051名低剂量CT肺癌筛查参与者,利用NCI CT剂量计算系统和性别、体型特异性成人模型估算器官吸收剂量与有效剂量。中位研究级有效剂量为2.07 mSv,参与者累计有效剂量中位数为5.94 mSv,并分析了扫描范围相关的剂量不确定性。
要点
- NLST低剂量CT筛查中位研究级有效剂量为2.07 mSv,累计有效剂量中位数为5.94 mSv。
- 肺、乳腺、心壁研究级中位剂量接近,约3.93–3.94 mGy,骨髓剂量明显较低。
- 甲状腺剂量受扫描范围不确定性影响最大,平均变异系数达21.1%。
核心结论
- 基于NLST低剂量CT筛查数据估算了参与者级累计器官剂量和有效剂量,并描述不同器官和体型组间的剂量差异。
- 肺、乳腺、心壁的累计中位剂量约为11.3–11.4 mGy,活性骨髓累计中位剂量为3.63 mGy。
研究设计与样本
- 回顾性剂量学研究,纳入NLST(LSS和ACRIN两部分)25051名低剂量CT肺癌筛查参与者。
- 排除缺乏有效制造商适用管电流时间输入的检查后,共纳入69601次研究级筛查检查。
- 将影像序列元数据与年龄、性别、身高和体重关联,并使用NCI CT剂量计算系统及性别、体型特异性成人模型计算器官剂量。
- 采用50次随机模拟评估与扫描范围相关的剂量不确定性。
诊断标准与关键数值
- 研究级容积CT剂量指数中位数为3.30 mGy。
- 研究级肺、乳腺、心壁和活性骨髓剂量中位数分别为3.93、3.94、3.94和1.26 mGy,有效剂量为2.07 mSv。
- 参与者累计肺、乳腺、心壁和活性骨髓剂量中位数分别为11.30、11.39、11.41和3.63 mGy,有效剂量为5.94 mSv。
- 扫描范围相关剂量不确定性以甲状腺最大,平均变异系数为21.1%,照射野内器官不确定性较低。
临床应用与阅片要点
- 低剂量CT肺癌筛查的重复检查会形成累计有效剂量,需在剂量报告中关注累计而非单次剂量。
- 肺、乳腺、心壁因位于照射野内,单次和累计剂量水平相近,阅片及剂量管理时可将三者视为相似受照水平器官。
- 甲状腺剂量不确定性较大,评估甲状腺相关风险时应谨慎解释剂量估算结果。
局限性
- 回顾性研究设计,排除了缺乏有效管电流时间输入的检查,可能存在选择偏倚。
- 甲状腺等边界器官剂量受扫描范围不确定性影响较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Organ-specific dose estimates are needed to characterize radiation exposure from repeated low-dose computed tomography (CT) lung cancer screening in the National Lung Screening Trial (NLST). The objective was to estimate study-level doses and participant-level cumulative doses in the NLST CT screening cohort.
MATERIALS AND METHODS: This retrospective dosimetry study included 25,051 NLST CT screening participants from the Lung Screening Study and American College of Radiology Imaging Network components after excluding participants with any examination lacking a valid manufacturer-appropriate tube current-time input. Image-series metadata were linked with age, sex, height, and weight, and then valid records were grouped into 69,601 study-level screening examinations. Organ absorbed doses and effective dose were calculated using the National Cancer Institute dosimetry system for Computed Tomography with sex- and body-size-specific adult phantoms. Scan-range-related dose uncertainty was assessed with 50 stochastic simulations.
RESULTS: Participants underwent a mean of 2.78 study-level screening examinations; the median study-level volume CT dose index was 3.30 mGy. Median (interquartile range) study-level lung, breast, heart wall, active marrow, and effective doses were 3.93 (3.13-4.96), 3.94 (3.14-5.04), 3.94 (3.14-5.01), and 1.26 (0.99-1.60) mGy, and 2.07 (1.65-2.59) mSv, respectively. Corresponding cumulative participant-level doses were 11.30 (8.89-14.50), 11.39 (9.01-14.75), 11.41 (8.93-14.66), and 3.63 (2.79-4.66) mGy, and 5.94 (4.69-7.64) mSv. Scan-range-related dose uncertainty was greatest for thyroid dose (mean coefficient of variation, 21.1%) and low for in-field organs.
CONCLUSION: Using NLST low-dose CT screening data, we estimated participant-level cumulative organ and effective doses and characterized variation across organs and body-size groups.
引用
- Lee, Moroz, Hwang, et al. Full-Cohort Organ Dose Assessment from Low-Dose CT Lung Cancer Screening in the National Lung Screening Trial. Acad Radiol. 2026. PMID: 42907269. doi:10.1016/j.acra.2026.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。